Printed From BioPortfolio.com
EMA responds to criticism of its cancer drug approvals
05:13 EDT 17 Oct 2017 | Pharmafile
The EMA received a broadside just less than two week ago from a group of researchers that had studied data from cancer drug approvals, with the suggestion that just fewer than half failed to showed any statistically significant benefit.
The treatments analysed were from the period 2009 to 2013, and included a total of 48 treatments for 68 different indications. Of these indications, 39 were found to be ineffective at boosting quality of life or improving survival on initial application.
Original Article: EMA responds to criticism of its cancer drug approvals
